Theageneio Cancer Hospital
- Address
- Simeonidi Alex 2, 546 39 Thessaloniki, Greece
Theageneio Cancer Hospital - Comprehensive Oncology Research Center
Theageneio Cancer Hospital is a leading oncology research institution conducting advanced clinical trials across multiple cancer types. The center specializes in innovative immunotherapy approaches and targeted treatments, with particular expertise in studying immune checkpoint inhibitors, antibody-drug conjugates, and personalized cancer therapy. Their research portfolio demonstrates a commitment to improving outcomes in both solid tumors and hematologic malignancies.
- Melanoma and skin cancer immunotherapy, including combination checkpoint inhibitor strategies with fianlimab and cemiplimab
- Lung cancer therapeutics, focusing on non-small cell lung cancer (NSCLC) with targeted agents like repotrectinib for ROS1-positive disease and novel antibody-drug conjugates
- Gastrointestinal malignancies, including advanced studies in colon cancer with mismatch repair deficiency (dMMR/MSI-H) and high-risk urothelial carcinoma
- Hematologic cancers, encompassing multiple myeloma with stem cell transplant approaches and diffuse large B-cell lymphoma (DLBCL) with bispecific antibody therapy
The hospital's research program emphasizes adjuvant and perioperative treatment strategies aimed at preventing cancer recurrence, as evidenced by studies in breast cancer endocrine therapy and post-surgical melanoma prevention. With trials evaluating disease-free survival, progression-free survival, and minimal residual disease monitoring, Theageneio Cancer Hospital contributes significantly to advancing precision oncology and improving long-term outcomes for cancer patients across diverse therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 142 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 136 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1European Myeloma Network B.V.8trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Theageneio Cancer Hospital
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic Comparison of JPB898 and Nivolumab in Patients with Resected Stage IIB, IIC, or III Melanoma in the Adjuvant Setting | H e x a l AG | Phase I | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 142 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 24 | Unknown | 2020-05-15 | 2026-07-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.